Liver transplantation, rejection, withdrawal of immunosuppressions Injury, Occupational Diseases, Poisoning Failure and rejection of transplanted organs and tissues
Conditions
Interventions
26 liver recipients who had been free of rejection while on immunosuppressive agents for a minimum of two years will be randomised to receive either 15 mg/kg of ursodeoxycholic acid (UDCA) (N = 14) or
Sponsors
University of Western Ontario (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Recipients of liver transplantation at the University of Western Ontario, Canada who had stable graft function (no clinical or biochemical evidence of liver disease) for a minimum of two years were offered TIW if they met the following criteria: 1. No documented rejection episodes for at least 24 months prior to the study 2. A minimum post-transplant follow up period of at least 2 years 3. A history of compliance with medications, blood testing for laboratory analyses and in the case of patients transplanted for alcohol-induced liver disease, abstinence from all alcohol beverages during the study period
Exclusion criteria
Exclusion criteria: 1. Patients requiring triple anti-rejection therapy for frequent or severe episodes of rejection in the past 2. More than one liver transplant 3. Requiring anti rejection therapy for non-liver disorders (psoriasis, rheumatoid arthritis [RA] etc)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Biochemical and histological evidence of rejection 2. Graft dysfunction without rejection 3. Recurrence of pre-transplant disease 4. Six months without immunosuppression and no rejection or dysfunction on repeat liver biopsy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Development of renal failure 2. Hypertension 3. Extent of liver enzymes abnormalities 4. Safety and compliance | — |
Countries
Canada
Outcome results
None listed